Kelly Paul Edward
Known title: DirectorCIK: 0001658544
Kelly Paul Edward's purchase track record
How the stock did after each of Kelly Paul Edward's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
Purchases measured
3
of 3 since September 9, 2024
Stock higher 6 months later
67%
3 months: 67%
Median 6-month return
+213.2%
3 months: +40.1%
Beat the S&P 500
67%
median +204.8% vs. index
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 11/5/2025 | RLMD | $198K | +45.4% | +213.2% | +8.4% |
| 5/16/2025 | RLMD | $86K | +40.1% | +756.8% | +13.0% |
| 9/9/2024 | RLMD | $65K | -82.8% | -90.3% | +2.6% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| RLMD | ▲ Buy | Open Market | 90,000 | $198K | 11/5/2025 | View on chart |
| RLMD | ▲ Buy | Open Market | 200,000 | $86K | 5/16/2025 | View on chart |
| RLMD | ▲ Buy | Open Market | 25,000 | $65K | 9/9/2024 | View on chart |
| RLMD | ▲ Buy | Option Exercise | 10,000 | $32K | 4/4/2022 | View on chart |
| RLMD | ▼ Sell | Open Market | 10,000 | $300K | 4/4/2022 | View on chart |
| RLMD | ▲ Buy | Option Exercise | 20,000 | $65K | 1/3/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
Relmada Releases Q2 2026 Earnings Call Transcript
Relmada Therapeutics posted the full transcript of its Q2 2026 earnings call. The discussion covered the company’s financial performance for the quarter, updated guidance, and strategic priorities. Investors can review the transcript for details on revenue, expenses, and future outlook. The release provides a comprehensive view of the company’s recent results.
Relmada Releases Q2 2026 Earnings Call Transcript. Relmada Therapeutics posted the full transcript of its Q2 2026 earnings call. The discussion covered the company’s financial performance for the quarter, updated guidance, and strategic priorities. Investors can review the transcript for details on revenue, expenses, and future outlook. The release provides a comprehensive view of the company’s recent results.